Clinical trial

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

NCT05352178

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-04-20

PhasePHASE3

Study timeline

Study start (actual)2022-04-20Date precision: day

Registry last updated2024-07-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Prostate Cancer Recurrentunresolved

Prostate Cancer Metastaticverified · MONDO: metastatic prostate carcinoma

Metastatic Cancerverified · MONDO: metastatic malignant neoplasm

Oligometastatic Diseaseunresolved

Oligometastasisunresolved

Hormone Sensitive Prostate Cancerunresolved

Interventions

Radiotherapy (SBRT) and/or surgery (metastasectomy)OTHER

Androgen deprivation therapyDRUG

Androgen receptor targeted therapyDRUG

Sponsors & collaborators

Universitaire Ziekenhuizen KU Leuvenlead sponsor

Mapped research locations

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05352178 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.